Plectranthus barbatus: A review of phytochemistry, ethnobotanical uses and pharmacology part 2

Planta Medica

Volumn 76, Issue 8, 2010, Pages 753-765

  Alasbahi, Rawiya H ^a   Melzig, Matthias F ^b  

^a UNIVERSITY OF ADEN   (Yemen)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

6(3dimethylaminopropionyl)forskolin hydrochloride (NKH477); Ethnobotanical uses; Forskolin; Lamiaceae; Pharmacology; Phytochemistry; Plectranthus barbatus

Indexed keywords

1 ACETYLFORSKOLIN; 1,9 DIDEOXYFORSKOLIN; 13 EPI 9 DEOXY FORSKOLIN; 13 EPI SCLAREOL; 7 DEACETYLFORSKOLIN; 9 DEOXYFORSKOLIN; AMITRIPTYLINE; BARBATUSIN; BARBATUSOL; COLEON C; CROMOGLYCATE DISODIUM; CYCLIC AMP; CYTOCHROME P450 3A; DOBUTAMINE; DOXORUBICIN; FORSKODITERPENOSIDE DERIVATIVE; FORSKOLIN DERIVATIVE; FSK 88; ISOFORSKOLIN; ISOPRENALINE; NITROPRUSSIDE SODIUM; PAPAVERINE; PLANT EXTRACT; PLECTRANTHUS BARBATUS EXTRACT; PLECTRIN; PLECTRINON A; SAPONIN; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ADJUVANT ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ASTHMA; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG MEGADOSE; EHRLICH ASCITES TUMOR; ERYTHEMA; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HAIR LOSS; HUMAN; LIVER PROTECTION; MOOD; NONHUMAN; OBESITY; OTITIS; PHYTOCHEMISTRY; PLANT LEAF; PLANT ROOT; PLANT STEM; PLECTRANTHUS; PLECTRANTHUS BARBATUS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SPASMOLYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

FORSKOLIN; LAMIACEAE; PHYTOTHERAPY; PLANTS, MEDICINAL;

LAMIACEAE; PLECTRANTHUS; PLECTRANTHUS BARBATUS;

EID: 77952894219     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1240919     Document Type: Review

References (238)

1. Matu E N., van Staden J. Antibacterial and anti-inflammatory activities of some plants used for medicinal purposes in Kenya. J Ethnopharmacol 2003 87 35-41
2. Runyoro D K. B., Matee M I. N., Ngassapa O D., Joseph C C., Mbwambo Z H. Screening of Tanzanian medicinal plants for anti- Candida activity. BMC Complement Altern Med 2006 6 11
3. Tamasiro V, Davino S C., Freitas P C. D., Barros S B. M. In vitro antioxidant activity of Coleus barbatus (Andr.) Benth (false boldo) and Peumus boldo (Molina) (Boldo do Chile): a comparative study. Rev Farm Bioquim Univ Sao Paulo 1998 34 15-17
4. Costa M C. C. D., Nascimento S C. Actividade citotxica de Plectranthus barbatus Andr. (Lamiaceae). Acta Farm Bonaer 2003 22 155-158
5. de Souza N J., Dohadwalla A N., Reden J. Forskolin: a labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev 1983 3 201-219
6. Kelecom A. Isolation, structure determination, and absolute configuration of barbatusol, a new bioactive diterpene with a rearranged abietane skeleton from the labiate Coleus barbatus. Tetrahedron 1983 39 3603-3608
7. Bhakuni D S., Dhar M L., Dhar M M., Dhawan B N., Gupta B, Srimal R C. Screening of Indian plants for biological activity. Indian J Exp Biol 1971 9 91
8. Staudinger J L., Ding X, Lichti K. Pregnane X receptor and natural products: beyond drug-drug interactions. Expert Opin Drug Metab Toxicol 2006 2 847-857
9. Kubo I, Matsumoto T, Tori M, Asakawa Y. Structure of plectrin, an aphid antifeedant diterpene from Plectranthus barbatus. Chem Lett 1984 9 1513-1516
10. Zelnik R, Lavie D, Levy E C., Wang A H. J., Paul I C. Barbatusin and cyclobutatusin, two novel diterpenoids from Coleus barbatus Bentham. Tetrahedron 1977 33 1457-1467
11. Yadava J N. S., Gupta S, Ahmad I, Varma N, Tandon J S. Neutralization of enterotoxins of Escherichia coli by coleonol (forskolin) in rabbit and guinea pig ileal loop models. Indian J Anim Sci 1995 65 1177-1181
12. Almeida F C., Lemonica I P. The toxic effects of Coleus barbatus B on the different periods of pregnancy in rats. J Ethnopharmacol 2000 73 53-60
13. Camara C C., Nascimento N R., Macedo-Filho C L., Almeida F B., Fonteles M C. Antispasmodic effect of the essential oil of Plectranthus barbatus and some major constituents on the guinea-pig ileum. Planta Med 2003 69 1080-1085
14. Fischman L A., Skorupa L A., Souccar C, Lapa A J. The water extract of Coleus barbatus Benth decreases gastric secretion in rats. Mem Inst Oswaldo Cruz 1991 86 (Suppl.2) 141-143
15. Schultz C, Bossolani M P., Torres L M. B., Lima-Landman M T. R., Lapa A J., Souccar C. Inhibition of the gastric H+, K+-ATPase by plectrinone A, a diterpenoid isolated from Plectranthus barbatus Andrews. J Ethnopharmacol 2007 111 1-7
16. Battochio A P., Sartori M S., Coelho C A. Water-soluble extract of Coleus barbatus modulates weight gain, energy utilization and lipid metabolism in secondary biliary cirrhosis: an experimental study in young rats. Acta Cir Bras 2005 20 229-236
17. Han L K., Morimoto C, Yu R H., Okuda H. Effects of Coleus forskohlii on fat storage in ovariectomized rats. Yakugaku Zasshi 2005 125 449-453
18. Zhang R, Kong L, Wang G, Zuo G. Manufacture of dripping pills containing Coleus forskohlii extract. Chinese Patent CN 1682840 A. 2005
19. Liu J, Zhang J, Chen Z, Xu Y L., Jin Q D. Chinese medicine composition for treating asthma and cough and its preparation. Chinese Patent CN 1872146 A. 2006
20. Jin Q, Chen Z, Zhang G. A Chinese medicinal granule for treating bronchial asthma containing flos colei esquirolii, radix peucedani, and radix glycyrrhizae. Chinese Patent CN 1154861 A. 1997
21. Tanaka R. Dentifrice compositions containing taurine and Coleus forskohlii extract. Japanese Patent JP 2003171250 A. 2003
22. Godard M P., Johnson B A., Richmond S R. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res 2005 13 1335-1343
23. Badmaev V, Majeed H. Compositions for physiological increase of male and female hormones with diterpene forskolin and its derivatives. Patent Application No. AU 2007200442 A1. 2007
24. Yamashita A, Takashita T, Ishihara T. Antiobesity agents and food, beverage, and medical compositions containing bergenin and forskolin and/or astilbin. Japanese Patent JP 2004091464 A. 2004
25. Miura M. Foods containing -glucosidase inhibitors for restricting calories. Japanese Patent JP 2007195510 A. 2007
26. Saito M, Hara M, Hirotsu S. Lipid decomposition promoters and cosmetics containing plant extracts. Japanese Patent JP 2000016916 A. 2000
27. Kawakami T. Anti-allergy compositions containing Coleus forskohlii root extract and cinnamon extract. Japanese Patent JP 2003252786 A. 2003
28. Bonte F, Meybeck A, Marechal C. Composition based on hydrated lipidic lamellar phases or on liposomes containing at least one derivative of labdane, or a plant extract containing it; cosmetic or pharmaceutical, particularly dermatological composition containing it. US Patent 5891464. 1999
29. Adachi H, Ehata S, Hayashi T. Antiaging cosmetics containing Coleus forskohlii root extracts and antioxidants. Japanese Patent JP 08176005 A. 1996
30. Majeed M, Prakash S. Composition and methods containing an antimicrobial essential oil extended from Coleus forskohlii. US Patent 6607712 B2. 2003
31. Lukhoba C W., Simmonds M S. J., Paton A J. Plectranthus: a review of ethnobotanical uses. J Ethnopharmacol 2006 103 1-24
32. Seamon K B., Padgett W, Daly J W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 1981 78 3363-3367
33. Daly J W., Padgett W, Seamon K B. Activation of cyclic AMP-generating systems in brain membranes and slices by the diterpene forskolin: augmentation of receptormediated responses. J Neurochem 1982 38 532-544
34. Fradkin J E., Cook G H., Kilhoffer M C., Wolff J. Forskolin stimulation of thyroid adenylate cyclase and cyclic 3,5-adenosine monophosphate accumulation. Endocrinology 1982 111 849-856
35. Birnbaumer L, Stengel D, Desmier M, Hanoune J. Forskolin regulation of liver membrane adenylyl cyclase. Eur J Biochem 1983 136 107-112
36. Mettauer M, Giesen E M., Imbs J L., Schmidt M, Schwartz J. Forskolin increases cAMP production in a kidney cell line (MDCK). Libr Compend 1983 11 887
37. Seamon K B., Daly J W., Metzger H, de Souza N J., Reden J. Structure-activity relationships for activation of adenylate cyclase by the diterpene forskolin and its derivatives. J Med Chem 1983 26 436-439
38. Seamon K B., Wetzel B. Interaction of forskolin with dually regulated adenylate cyclase. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984 17 91-99
39. Seamon K B. Forskolin and adenylate cyclase: new opportunities in drug design. Annu Rep Med Chem 1984 19 293-302
40. Daly J W. Forskolin, adenylate cyclase, and cell physiology: an overview. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984 17 81-89
41. Seamon K B. Activation of hormone-sensitive adenylate cyclase by forskolin. Drug Dev Res 1985 6 181-192
42. Seamon K B. Forskolin and adenylate cyclase. ISI atlas of science. Pharmacology 1987 1 250-253
43. Pfeuffer E, Mollner S, Pfeuffer T. Adenylate cyclase from bovine brain cortex: purification and characterization of the catalytic unit. EMBO J 1985 4 3675-3679
44. Smigel M D. Purification of the catalyst of adenylate cyclase. J Biol Chem 1986 261 1976-1982
45. Hacker B M., Tomlinson J E., Wayman G A., Sultana R, Chan G, Villacres E, Disteche C, Storm D R. Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9). Genomics 1998 50 97-104
46. Defer N, Best-Belpomme M, Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol 2000 279 F400-F416
47. Dahle M K., Myhre A E., Aasen A O., Wang J E. Effects of forskolin on Kupffer cell production of interleukin-10 and tumor necrosis factor alpha differ from those of endogenous adenylyl cyclase activators: possible role for adenylyl cyclase 9. Infect Immun 2005 73 7290-7296
48. Ammon H P., Mller A B. Forskolin: from an ayurvedic remedy to a modern agent. Planta Med 1985 51 473-477
49. Bhat S V., Dohadwalla A N., Bajwa B S., Dadkar N K., Dornauer H, de Souza N J. The antihypertensive and positive inotropic diterpene forskolin: effects of structural modifications on its activity. J Med Chem 1983 26 486-492
50. Lindner E, Metzger H. The action of forskolin on muscle cells is modified by hormones, calcium ions and calcium antagonists. Arzneimittelforschung 1983 33 1436-1441
51. Iwase M, Ishikawa Y, Shen Y T., Shannon R P., Sato N, Ganguly P K., Eki T, Vatner D F., Vatner S F. Neurally mediated cardiac effects of forskolin in conscious dogs. Am J Physiol 1996 271 H1473-H1482
52. ++ level and contraction in vascular smooth muscle. J Pharmacol Exp Ther 1989 249 895-900 (Pubitemid 19166674)
53. Rembold C M., Chen X L. Mechanisms responsible for forskolin-induced relaxation of rat tail artery. Hypertension 1998 3 872-877
54. White R E., Kryman J P., El-Mowafy A M., Han G, Carrier G O. cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BKCa channel activity in coronary artery smooth muscle cells. Circ Res 2000 86 897-905
55. Linz W, Wiemer G, Schlkens B A. Effects of colforsin, trequinsin and isoprenaline on norepinephrine-induced contractions and cyclic nucleotide levels of isolated vascular tissue. Arzneimittelforschung 1988 38 240-243
56. Bristow M R., Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest 1984 74 212-223
57. Kramer W, Thormann J, Kindler M, Schlepper M. Effects of forskolin on left ventricular function in dilated cardiomyopathy. Arzneimittelforschung 1987 37 364-367
58. Baumann G, Felix S, Sattelberger U, Klein G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990 16 93-100
59. Vaden S L., Adams H R. Inotropic, chronotropic and coronary vasodilator potency of forskolin. Eur J Pharmacol 1985 118 131-137
60. Wysham D G., Brotherton A F., Heistad D D. Effects of forskolin on cerebral blood flow: implications for a role of adenylate cyclase. Stroke 1986 17 1299-1303
61. Agarwal K C., Zielinski B A., Maitra R S. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep. Thromb Haemost 1989 61 106-110
62. Graber S E., Hawiger J. Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets. J Biol Chem 1982 257 14606-14609
63. Kariya T, Morito F, Sakai T, Takahata K, Yamanaka M. Effect of forskolin on platelet deaggregation and cyclic AMP generation. Naunyn Schmiedebergs Arch Pharmacol 1985 331 119-121
64. Salim M L. D. Effect of aspirin and forskolin on blood platelet function. Alex J Pharm Sci 2003 17 151-155
65. de Chaffoy de Courcelles D, Roevens P, Van Belle H. Prostaglandin E1 and forskolin antagonize C-kinase activation in the human platelet. Biochem J 1987 244 93-99
66. Doni M G., Deana R, Bertoncello S, Zoccarato F, Alexandre A. Forskolin and prostacyclin inhibit fluoride induced platelet activation and protein kinase C dependent responses. Biochem Biophys Res Commun 1988 156 1316-1323
67. Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res 2004 114 265-273
68. Wong S, Mok W, Phaneuf S, Katz S, Salari H. Forskolin inhibits platelet-activating factor binding to platelet receptors independently of adenylyl cyclase activation. Eur J Pharmacol 1993 245 55-61
69. Agarwal K C., Parks Jr R E. Forskolin: a potential antimetastatic agent. Int J Cancer 1983 32 801-804
70. Yoshizawa J, Yoshida K, Fujikawa T, Tanabe A, Sakurai K. Inhibitory effects of forskolin on hepatic metastasis from human colon cancer in nude mice. Nippon Geka Gakkai Zasshi 1995 96 26-30
71. Thulesius O, Christenson J T. Methods for preventing thrombosis; and surgical implant having reduced platelet deposition characteristics. US Patent 4909799. 1990
72. Siegl A M., Moroff G. Effect of forskolin on the maintenance of platelet properties during storage. J Lab Clin Med 1986 108 354-359
73. Chang J, Hand J M., Schwalm S, Dervinis A, Lewis A J. Bronchodilating activity of forskolin in vitro and in vivo. Eur J Pharmacol 1984 101 271-274
74. Kreutner W, Chapman R W., Gulbenkian A, Tozzi S. Bronchodilator and antiallergy activity of forskolin. Eur J Pharmacol 1985 111 1-8
75. Tsukawaki M, Suzuki K, Suzuki R, Takagi K, Satake T. Relaxant effects of forskolin on guinea pig tracheal smooth muscle. Lung 1987 165 225-237
76. Yousif M H. M., Thulesius O. A pharmacological study of bronchodilator properties of NKH477, forskolin, and -agonists on guinea pig and ovine isolated bronchioles. Drug Dev Res 2000 51 169-176
77. Yousif M H., Thulesius O. Forskolin reverses tachyphylaxis to the bronchodilator effects of salbutamol: an in-vitro study on isolated guinea-pig trachea. J Pharm Pharmacol 1999 51 181-186
78. Kreutner W, Green M J., Shue H-J, Saksena A K. Method for treating allergic reactions with forskolin. US Patent 4782082. 1988
79. Lichey I, Friedrich T, Priesnitz M, Biamino G, Usinger P, Huckauf H. Effect of forskolin on methacholine-induced bronchoconstriction in extrinsic asthamtics. Lancet 1984 2 167
80. Kaik G, Witte P U. Protective effect of forskolin in acetylcholine provocation in healthy probands. Comparison of 2 doses with fenoterol and placebo. Wien Med Wochenschr 1986 136 637-641
81. Gonzlez-Snchez R, Trujillo X, Trujillo-Hernndez B, Vsquez C, Huerta M, Elizalde A. Forskolin versus sodium cromoglycate for prevention of asthma attacks: a single-blinded clinical trial. J Int Med Res 2006 34 200-207
82. Bauer K, Dietersdorfer F, Sertl K, Kaik B, Kaik G. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther 1993 53 76-83 (Pubitemid 23036690)
83. Yang C M., Pan S L., Chiu C T., Lin C C., Hsu Y M. Effect of forskolin on endothelin-induced phosphoinositide hydrolysis and calcium mobilization in cultured canine tracheal smooth muscle cells. J Auton Pharmacol 1998 18 213-221
84. Schramm C M., Chuang S T., Grunstein M M. cAMP generation inhibits inositol 1,4,5-trisphosphate binding in rabbit tracheal smooth muscle. Am J Physiol 1995 269 L715-L719
85. Zhu S, White R E., Barman S A. Effect of PKC isoenzyme inhibition on forskolin-induced activation of BKCa channels in rat pulmonary arterial smooth muscle. Lung 2006 184 89-97
86. 3 receptor. Respir Res 2006 7 34
87. Tajimi M, Hori M, Mitsui M, Ozaki H, Karaki H. Inhibitory effect of forskolin on myosin phosphorylation-dependent and independent contractions in bovine tracheal smooth muscle. J Smooth Muscle Res 1995 31 129-142
88. Tolloczko B, Jia Y L., Martin J G. Effects of cAMP on serotonin evoked calcium transients in cultured rat airway smooth muscle cells. Am J Physiol 1997 272 L865-L871
89. Sakai J, Oike M, Hirakawa M, Ito Y. Theophylline and cAMP inhibit lysophosphatidic acid-induced hyperresponsiveness of bovine tracheal smooth muscle cells. J Physiol 2003 549 171-180
90. Kaur M, Holden N S., Wilson S M., Sukkar M B., Chung K F., Barnes P J., Newton R, Giembycz M A. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 2008 295 L505-L514
91. Musa N L., Ramakrishnan M, Li J, Kartha S, Liu P, Pestell R G., Hershenson M B. Forskolin inhibits cyclin D1 expression in cultured airway smooth-muscle cells. Am J Respir Cell Mol Biol 1999 20 352-358
92. Kassel K M., Wyatt T A., Panettieri Jr R A., Toews M L. Inhibition of human airway smooth muscle cell proliferation by -2-adrenergic receptors and cAMP is PKA independent: evidence for EPAC involvement. Am J Physiol Lung Cell Mol Physiol 2008 294 L131-L138
93. Prostran M, Varagi V M. The effect of forskolin on the isometric contraction of the isolated hemidiaphragm of the rat. Br J Pharmacol 1986 88 791-797 (Pubitemid 16013085)
94. Takahashi S, Moriwaki K, Himeno S, Kuroshima T, Shinomura Y, Hamabe S, Kurokawa M, Saito R, Kitani T, Tarui S. Forskolin-induced cyclic AMP production and gastric acid secretion in dispersed rabbit parietal cells: novel evidence for a major role of cyclic AMP in acid release. Life Sci 1983 33 1401-1408
95. Choquet A, Magous R, Galleyrand J C., Bali J P. Is forskolin a stimulant of gastric secretion? C R Seances Soc Biol Fil 1988 182 335-343
96. Hersey S J., Miller M, Norris S H. Forskolin: a new biochemical tool for studying gastric secretion. Prog Clin Biol Res 1983 126 329-341
97. Hersey S J., Owirodu A, Miller M. Forskolin stimulation of acid and pepsinogen secretion by gastric glands. Biochim Biophys Acta 1983 755 293-299 (Pubitemid 13153884)
98. Modlin I M., Schafer D E., Tyshkov M, Ballantyne G H., Fratesi G R., Roberts J R., Zdon M J. Forskolin (cyclic adenosine monophosphate)-dependent protein phosphorylation in isolated gastric glands. Arch Surg 1986 121 330-337
99. Iwatsuki K, Horiuchi A, Yamagishi F, Chiba S. Effects of forskolin on pancreatic exocrine secretion and cyclic nucleotide concentrations of the dog pancreas. Arch Int Pharmacodyn Ther 1987 286 320-328
100. Dubey M P., Srimal R C., Nityanand S, Dhawan B N. Pharmacological studies on coleonol, a hypotensive diterpene from Coleus forskohlii. J Ethnopharmacol 1981 3 1-13
101. Mimura M. Functional food for the bowel movement improvement. Japanese Patent JP 2007097572 A. 2007
102. Morita T, Wheeler M A., Miyagawa I, Kondo S, Weiss R M. Effects of forskolin on contractility and cyclic AMP levels in rabbit detrusor muscle. Tohoku J Exp Med 1986 149 283-285 (Pubitemid 17172081)
103. Truss M C., Uckert S, Stief C G., Kuczyk M, Schulz-Knappe P, Forssmann W G., Jonas U. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro. Neurourol Urodyn 1996 15 59-70
104. Schwertschlag U, Hackenthal E. Forskolin stimulates renin release from the isolated perfused rat kidney. Eur J Pharmacol 1982 84 111-113 (Pubitemid 12005366)
105. Bishop B L., Duncan M J., Song J, Li G, Zaas D, Abraham S N. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat Med 2007 13 625-630
106. Vedernikov Y P., Syal A S., Okawa T, Saade G R., Garfield R E. Adenylate cyclase and potassium channels are involved in forskolin- and 1,9-dideoxyforskolin-induced inhibition of pregnant rat uterus contractility. Am J Obstet Gynecol 2000 182 620-624
107. Tamaki T, Hasui K, Shoji T, Aki Y, Kiyomoto H, Iwao H, Abe Y. Forskolin preferentially dilates the afferent arteriole in the canine kidney. Jpn J Pharmacol 1991 55 161-164
108. Caprioli J, Sears M. Forskolin lowers intraocular pressure in rabbits, monkeys, and man. Lancet 1983 1 958-960
109. Caprioli J, Sears M, Bausher L, Gregory D, Mead A. Forskolin lowers intraocular pressure by reducing aqueous inflow. Invest Ophthalmol Vis Sci 1984 25 268-277
110. Burstein N L., Sears M L., Mead A. Aqueous flow in human eyes is reduced by forskolin, a potent adenylate cyclase activator. Exp Eye Res 1984 39 745-749
111. Caprioli J, Sears M. The adenylate cyclase receptor complex and aqueous humor formation. Yale J Biol Med 1984 57 283-300
112. Sears M L. Regulation of aqueous flow by the adenylate cyclase receptor complex in the ciliary epithelium. Am J Ophthalmol 1985 100 194-198
113. Bartels S P., Lee S R., Neufeld A H. Forskolin stimulates cyclic AMP synthesis, lowers intraocular pressure and increases outflow facility in rabbits. Curr Eye Res 1982/1983 2 673-681
114. Ramachandran C, Satpathy M, Mehta D, Srinivas S P. Forskolin induces myosin light chain dephosphorylation in bovine trabecular meshwork cells. Curr Eye Res 2008 33 169-176
115. Bartels S P., Lee S R., Neufeld A H. The effects of forskolin on cyclic AMP, intraocular pressure and aqueous humor formation in rabbits. Curr Eye Res 1987 6 307-320
116. Lee P Y., Podos S M., Serle J B., Camras C B., Severin C H. Intraocular pressure effects of multiple doses of drugs applied to glaucomatous monkey eyes. Arch Ophthalmol 1987 105 249-252
117. Matsumoto S, Yamashita T, Araie M, Kametani S, Hosokawa T, Takase M. The ocular penetration of topical forskolin and its effects on intraocular pressure, aqueous flow rate and cyclic AMP level in the rabbit eye. Jpn J Ophthalmol 1990 34 428-435
118. Santana C, Menendez-Pelaez A, Reiter R J., Guerrero J M. Treatment with forskolin for 8 hours during the day increases melatonin synthesis in the Syrian hamster pineal gland in organ culture: the long lag period is required for RNA synthesis. J Neurosci Res 1990 25 545-548
119. Michelet J F., Gautier B, Gaillard O, Bernard B A., Benech F. Human hair follicle pigmentary unit as a direct target for modulators of melanogenesis, as studied by [C]-2-thiouracil incorporation. Exp Dermatol 2009 18 414-416
120. Nishizawa H, Kono T, Yokoyama D, Masuda M. Effects of forskolin on hair follicular keratinocytes. Nippon Koshohin Kagakkaishi 2000 24 111-114
121. Hayashi T. Application of a new botanical ingredient Coleus extract to hair growth products. Fragr J 2000 28 45-49
122. Majeed M. Compositions and methods to treat alopecia. US Pat Appl Publ US 2008/0241285 A1. 2008
123. Lal B, Blumbach J, Dohadwalla A N., de Souza N J. Pharmaceutical compositions comprising labdane diterpenoid derivatives and pyrimido[6,1- a ]isoquinolin-4-one derivatives and their use. US Patent 5141942. 1992
124. D'Orazio J A., Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter S R., Nishimura E K., Ito S, Fisher D E. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006 443 340-344
125. Passeron T, Namiki T, Passeron H J., Le Pape E, Hearing V J. Forskolin protects keratinocytes from UVB-induced apoptosis and increases DNA repair independent of its effects on melanogenesis. J Invest Dermatol 2009 129 162-166
126. Majeed M. Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin. US Pat Appl Publ US 2008/0226571 A1. 2008
127. Halprin K M., Adachi K. Treatment of hyperplastic diseases of the skin with polyoxygenated labdanes. PCT Int Appl WO 8503637 A1. 1985
128. Piontek M, Hengels K J., Porschen R, Strohmeyer G. Protein kinase C and adenylate cyclase as targets for growth inhibition of human gastric cancer cells. J Cancer Res Clin Oncol 1993 119 697-699
129. Gtzkow K B., Naderi S, Blomhoff H K. Forskolin-mediated G1 arrest in acute lymphoblastic leukemia cells: phosphorylated pRB sequesters E2Fs. J Cell Sci 2002 115 1073-1082
130. Guan K, Liu H, Tan W. Relationship between expression of Ha-ras and inhibition of proliferation by forskolin in human gastric cancer cell line BGC-823. Shengwu Huaxue Zazhi 1995 11 401-405
131. Guan K, Liu H, Tan W. The effect of forskolin on protein kinase C and its subunits in human gastric cancer cell line BGC-823. Shengwu Huaxue Zazhi 1995 11 316-320
132. Wang X, Zhang L, Zhao S, Ma L. Effects of forskolin on cell proliferation in human gastric cancer cells. Zhongliu Fangzhi Zazhi 2003 10 928-930
133. Neviani P, Santhanam R, Trotta R, Notari M, Blaser B W., Liu S, Mao H, Chang J S., Galietta A, Uttam A, Roy D C., Valtieri M, Bruner-Klisovic R, Caligiuri M A., Bloomfield C D., Marcucci G, Perrotti D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005 8 355-368
134. McEwan D G., Brunton V G., Baillie G S., Leslie N R., Houslay M D., Frame M C. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res 2007 67 5248-5257
135. Zhang D, Ye C, Wang H. Antitumor composition containing forskolin, theophylline, IBMX and carboxyamidotriazole. Chinese Patent CN 1660434 A. 2005
136. Garca-Bermejo L, Prez C, Vilaboa N E., de Blas E, Aller P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci 1998 111 637-644
137. Watabe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya M. The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem 1996 271 14067-14073
138. Wu S I., Ma J, Qi H I., Zhang Y, Zhang X Y., Chen H I. Forskolin up-regulates metastasis-related phenotypes and molecules via protein kinase B, but not PI-3K, in H7721 human hepato-carcinoma cell line. Mol Cell Biochem 2003 254 193-202
139. Burns T W., Langley P E., Terry B E., Bylund D B., Forte L R. Alpha-2 adrenergic activation inhibits forskolin-stimulated adenylate cyclase activity and lipolysis in human adipocytes. Life Sci 1982 31 815-821
140. Okuda H, Morimoto C, Tsujita T. Relationship between cyclic AMP production and lipolysis induced by forskolin in rat fat cells. J Lipid Res 1992 33 225-231
141. Mooney R A., Swicegood C L., Marx R B. Coupling of adenylate cyclase to lipolysis in permeabilized adipocytes: direct evidence that an antilipolytic effect of insulin is independent of adenylate cyclase. Endocrinology 1986 119 2240-2248
142. Litosch I, Hudson T H., Mills I, Li S Y., Fain J N. Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes. Mol Pharmacol 1982 22 109-115 (Pubitemid 12097269)
143. Allen D O., Ahmed B, Naseer K. Relationships between cyclic AMP levels and lipolysis in fat cells after isoproterenol and forskolin stimulation. J Pharmacol Exp Ther 1986 238 659-664
144. Allen D O., Quesenberry J T. Quantitative differences in the cyclic AMP-lipolysis relationships for isoproterenol and forskolin. J Pharmacol Exp Ther 1988 244 852-858
145. Schimmel R J. Stimulation of cAMP accumulation and lipolysis in hamster adipocytes with forskolin. Am J Physiol 1984 246 C63-C68
146. Morimoto C, Kameda K, Tsujita T, Okuda H. Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells. J Lipid Res 2001 42 120-127
147. Majeed M, Bammi R K., Sankaran N, Ramanujam R, Kalkunte S S., Prakash S. Method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications. US Pat Appl Publ US 2006122261 A1. 2006
148. Greenway F L., Bray G A. Regional fat loss from the thigh in obese women after adrenergic modulation. Clin Ther 1987 9 663-669
149. Greenway F L., Bray G A., Heber D. Topical fat reduction. Obes Res 1995 3 (Suppl.4) 561S-568S
150. Furukawa Y, Matsumori A, Hirozane T, Matsui S, Sato Y, Ono K, Sasayama S. Immunomodulation by an adenylate cyclase activator, NKH477, in vivo and vitro. Clin Immunol Immunopathol 1996 79 25-35
151. Schorlemmer H U., Dickneite G, Sedlacek H H., de Souza N J., Dohadwalla A N. Use of the diterpene derivative forskolin for immunostimulation. US Patent 4578399. 1986
152. Curtin B F., Pal N, Gordon R K., Nambiar M P. Forskolin, an inducer of cAMP, upregulates acetylcholinesterase expression and protects against organophosphate exposure in neuro 2A cells. Mol Cell Biochem 2006 290 23-32
153. Morazzoni P, Bombardelli E. Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction. PCT Int Appl WO 9636332 A1. 1996
154. Karaay B, Li G, Pantazis N J., Bonthius D J. Stimulation of the cAMP pathway protects cultured cerebellar granule neurons against alcohol-induced cell death by activating the neuronal nitric oxide synthase (nNOS) gene. Brain Res 2007 1143 34-45
155. Gupta P P., Srimal R C., Verma N, Tandon J S. Passive cutaneous anaphylactic inhibitory and mast cell stabilizing activity of coleonol and its derivative. Indian J Pharmacol 1994 26 150-152
156. Marone G, Columbo M, Triggiani M, Cirillo R, Genovese A, Formisano S. Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin. Biochem Pharmacol 1987 36 13-20
157. Dohadwalla A N., Mandrekar S S., Dadkar N K., Khandelwal Y, Rupp R H., de Souza N J. Labdane derivatives and their use as drugs. Patent DE 3502686 A1. 1986
158. Dohadwalla A N., Mandrekar S S., Dadkar N K., Khandelwal Y, Rupp R H., de Souza N J. Method of treating inflammatory diseases with labdan derivatives. US Patent 4724238. 1988
159. Maeda H, Ozawa H, Saito T, Irie T, Takahata N. Potential antidepressant properties of forskolin and a novel water-soluble forskolin (NKH477) in the forced swimming test. Life Sci 1997 61 2435-2442
160. Sano M, Seto-Ohshima A, Mizutani A. Forskolin supresses seizures induced by pentylenetetrazole in mice. Experientia 1984 40 1270-1271
161. Barraco R A., Phillis J W., Altman H J. Depressant effect of forskolin on spontaneous locomotor activity in mice. Gen Pharmacol 1985 16 521-524
162. Bersudsky Y, Kotler M, Shifrin M, Belmaker R H. A preliminary study of possible psychoactive effects of intravenous forskolin in depressed and schizophrenic patients. Short communication. J Neural Transm 1996 103 1463-1467
163. Vitolo O V., Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 2002 99 13217-13221
164. Wang X, Li X, Wang K, Zhou H, Xue B, Li L, Wang X. Forskolin cooperating with growth factor on generation of dopaminergic neurons from human fetal mesencephalic neural progenitor cells. Neurosci Lett 2004 362 117-121
165. Ahmad F, Khan M M., Rastogi A K., Kidwai J R. Insulin and glucagon releasing activity of coleonol (forskolin) and its effect on blood glucose level in normal and alloxan diabetic rats. Acta Diabetol Lat 1991 28 71-77
166. Yamamoto S, Nakadate T, Uzumaki H, Kato R. Lipoxygenase inhibitors and cyclic AMP-mediated insulin secretion caused by forskolin, theophylline and dibutyryl cyclic AMP. J Pharmacol Exp Ther 1985 233 176-180
167. Leclercq-Meyer V, Malaisse W J. Modulation of gliquidone action by forskolin in the pancreas of normal and GK rats. Am J Physiol 1997 273 E52-E58
168. Mulhall J P., Daller M, Traish A M., Gupta S, Park K, Salimpour P, Payton T R., Krane R J., Goldstein I. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol 1997 158 1752-1759
169. Liu J H., Li Y, Cao Z G., Ye Z Q. Influences of dibutyryl cyclic adenosine monophosphate and forskolin on human sperm motility in vitro. Asian J Androl 2003 5 113-115
170. Li Y, Liu J, Ye H, Ye Z. Influence of forskolin on human sperm motility. Zhongguo Nankexue Zazhi 2004 18 23-25
171. van Sande J, Cochaux P, Mockel J, Dumont J E. Stimulation by forskolin of the thyroid adenylate cyclase, cyclic AMP accumulation and iodine metabolism. Mol Cell Endocrinol 1983 29 109-119
172. Laurenza A, Sutkowski E M., Seamon K B. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends Pharmacol Sci 1989 10 442-447
173. Kashiwagi A, Huecksteadt T P., Foley J E. The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. J Biol Chem 1983 258 13685-13692
174. Joost H G., Steinfelder H J. Forskolin inhibits insulin-stimulated glucose transport in rat adipose cells by a direct interaction with the glucose transporter. Mol Pharmacol 1987 31 279-283
175. Sergeant S, Kim H D. Inhibition of 3-O-methylglucose transport in human erythrocytes by forskolin. J Biol Chem 1985 260 14677-14682 (Pubitemid 16210998)
176. Kim H D., Sergeant S, Shukla S D. Glucose transport in human platelets and its inhibition by forskolin. J Pharmacol Exp Ther 1986 236 585-589
177. + transport protein, GalP. J Biol Chem 1994 269 24870-24877
178. + channels is independent of adenylate cyclase activation. Science 1988 240 1652-1655
179. Matthias K, Seifert G, Reinhardt S, Steinhuser C. Modulation of voltage-gated K(+) channels Kv11 and Kv14 by forskolin. Neuropharmacology 2002 43 444-449
180. Ono K, Fozzard H A., Hanck D A. A direct effect of forskolin on sodium channel bursting. Pflugers Arch 1995 429 561-569
181. Asai T, Pelzer S, McDonald T F. Cyclic AMP-independent inhibition of cardiac calcium current by forskolin. Mol Pharmacol 1996 50 1262-1272
182. Park T J., Kim K T. Cyclic AMP-independent inhibition of voltage-sensitive calcium channels by forskolin in PC12 cells. J Neurochem 1996 66 83-88
183. +-induced responses in chromaffin cells. Eur J Pharmacol 1997 329 189-199
184. Shi L J., Liu L A., Wang C A. Effect of forskolin on acetylcholine- induced current in rat pheochromocytoma cells. Acta Pharmacol Sin 2000 21 281-285
185. Fan P. Antagonism by forskolin of the 5-HT3 receptor-mediated current in nodose ganglion neurons is independent of cyclic AMP. Brain Res 1994 650 16-19
186. Oz M, Zhang L, Spivak C E. Direct noncompetitive inhibition of 5-HT3 receptor-mediated responses by forskolin and steroids. Arch Biochem Biophys 2002 404 293-301
187. Wadler S, Wiernik P H. Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants. Cancer Res 1988 48 539-543
188. Morris D I., Speicher L A., Ruoho A E., Tew K D., Seamon K B. Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry 1991 30 8371-8379
189. Uboldi A D., Savage N. The adenylate cyclase activator forskolin partially protects L929 cells against tumour necrosis factor-alpha-mediated cytotoxicity via a cAMPindependent mechanism. Cytokine 2002 19 250-258
190. Sidhu J S., Omiecinski C J. Forskolin-mediated induction of CYP3A1mRNA expression in primary rat hepatocytes is independent of elevated intracellular cyclic AMP. J Pharmacol Exp Ther 1996 276 238-245
191. Dowless M S., Barbee J L., Borchert K M., Bocchinfuso W P., Houck K A. Cyclic AMP-independent activation of CYP3A4 gene expression by forskolin. Eur J Pharmacol 2005 512 9-13
192. Li Ping, Yang X L. Forskolin modulation of desensitization at GABAA and glycine receptors is not mediated by cAMP-dependent protein kinase in isolated carp amacrine-like cells. Pflugers Arch 2001 441 739-745
193. Middleton P, Jaramillo F, Schuetze S M. Forskolin increases the rate of acetylcholine receptor desensitization at rat soleus endplates. Proc Natl Acad Sci USA 1986 83 4967-4971
194. Miles K, Anthony D T., Rubin L L., Greengard P, Huganir R L. Regulation of nicotinic acetylcholine receptor phosphorylation in rat myotubes by forskolin and cAMP. Proc Natl Acad Sci USA 1987 84 6591-6595
195. Wagoner P K., Pallotta B S. Modulation of acetylcholine receptor desensitization by forskolin is independent of cAMP. Science 1988 240 1655-1657
196. Middleton P, Rubin L L., Schuetze S M. Desensitization of acetylcholine receptors in rat myotubes is enhanced by agents that elevate intracellular cAMP. J Neurosci 1988 8 3405-3412
197. Berger C E., Datta H K. Forskolin has a bimodal cAMP-independent effect on superoxide anion generation in isolated osteoclasts. Exp Physiol 2000 85 57-60
198. Kreiger N S., Stern P H. Effect of forskolin on bone in organ culture. Am J Physiol 1987 252 E44-E48
199. Ding X, Staudinger J L. Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase A signal transduction pathway. J Pharmacol Exp Ther 2005 312 849-856
200. Putnam W C., Swenson S M., Reif G A., Wallace D P., Helmkamp Jr G M., Grantham J J. Identification of a forskolin-like molecule in human renal cysts. J Am Soc Nephrol 2007 18 934-943
201. Yang W, Li X, Chen Z, Nie L, Wang B, Shen Z. Adenylate cyclase stimulation and ocular hypertension inhibition by forskolin analogs. Yanke Yanjiu 2001 19 1-4
202. Bhat S V., Bajwa B S., Dornauer H, de Souza N J., Fehlhaber H W. Structures and stereochemistry of new labdane diterpenoids from Coleus forskohlii Briq. Tetrahedron Lett 1977 19 1669-1672
203. Tandon J S., Jauhari P K., Singh R S., Dhar M M. Structures of three new diterpenes, coleonol B, coleonol C and deoxycoleonol isolated from Coleus forskohlii. Indian J Chem Sect B Org Chem Incl Med Chem 1978 16B 341-345
204. Shan Y, Xu L, Lu Y, Wang X, Zheng Q, Kong L, Niwa M. Diterpenes from Coleus forskohlii (Willd.) Briq. (Labiatae). Chem Pharm Bull 2008 56 52-56
205. Joost H G., Habberfield A D., Simpson I A., Laurenza A, Seamon K B. Activation of adenylate cyclase and inhibition of glucose transport in rat adipocytes by forskolin analogues: structural determinants for distinct sites of action. Mol Pharmacol 1988 33 449-453
206. Zerr P, Becherer U, Rodeau J L., Feltz A. Forskolin's structural analog 1,9-dideoxyforskolin has Ca2+ channel blocker-like action in rat cerebellar granule cells. Eur J Pharmacol 1996 303 101-108
207. Li Z, Wang J. A forskolin derivative, FSK88, induces apoptosis in human gastric cancer BGC823 cells through caspase activation involving regulation of Bcl-2 family gene expression, dissipation of mitochondrial membrane potential and cytochrome c release. Cell Biol Int 2006 30 940-946
208. Tandon J S., Roy R, Balachandran S, Vishwakarma R A. Epi-deoxycoleonol, a new antihypertensive labdane diterpenoid from Coleus forskohlii. Bioorg Med Chem Lett 1992 2 249-254
209. Sashidhara K V., Rosaiah J N., Kumar A, Bid H K., Konwar R, Chattopadhyay N. Cell growth inhibitory action of an unusual labdane diterpene, 13-epi-sclareol in breast and uterine cancers in vitro. Phytother Res 2007 21 1105-1108
210. Shan Y, Wang X, Zhou X, Kong L, Niwa M. Two minor diterpene glycosides and an eudesman sesquiterpene from Coleus forskohlii. Chem Pharm Bull 2007 55 376-381
211. Liu Y, Wu H, Wang X M., Liu J, Xing X. Use of coleon C extracted from Coleus as inhibitor for tumor growth and tumor cell proliferation. Chinese Patent CN 1899273 A. 2007
212. Majeed M, Kumar A, Nagabhushanam K, Prakash S. Process for preparing water soluble diterpenes and their applications. US Pat Appl Pub US 2005/0284812 A1. 2005
213. Hosono M, Takahira T, Fujita A, Fujihara R, Ishizuka O, Ohoi I, Tatee T, Nakamura K. Cardiovascular effects of NKH477, a novel potent water-soluble forskolin derivative. Eur J Pharmacol 1990 183 2110
214. Laurenza A, Khandelwal Y, de Souza N J., Rupp R H., Metzger H, Seamon K B. Stimulation of adenylate cyclase by water-soluble analogues of forskolin. Mol Pharmacol 1987 32 133-139
215. Saettone M F., Burgalassi S, Giannaccini B. Preparation and evaluation in rabbits of topical solutions containing forskolin. J Ocul Pharmacol 1989 5 111-118
216. Khandelwal Y, Rajeshwari K, Rajagopalan R, Swamy L, Dohadwalla A N., de Souza N J., Rupp R H. Cardiovascular effects of new water-soluble derivatives of forskolin. J Med Chem 1988 31 1872-1879
217. Tatee T, Narita A, Narita K, Izumi G, Takahira T, Sakurai M, Fujita A, Hosono M, Yamashita K, Enomoto K, Shiozawa A. Forskolin derivatives. I. Synthesis, and cardiovascular and adenylate cyclase-stimulating activities of water-soluble forskolins. Chem Pharm Bull (Tokyo) 1996 44 2274-2279
218. Himeta M, Sakashita Y, Fujita A, Hosono M, Nakamura K. Characterization of the vasodilating effects of NKH477, a novel forskolin derivative, in isolated rat aorta, canine arteries and rabbit femoral arteries and veins. Yakuri To Chiryo 1998 26 775-785
219. Hosono M. Cardiovascular effects of colforsin daropate hydrochloride, a novel drug for the treatment of acute heart failure. Nippon Yakurigaku Zasshi 1999 114 83-88
220. Hirota K, Yoshioka H, Kabara S, Koizumi Y, Abe H, Sato T, Matsuki A. Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Acta Anaesthesiol Scand 2002 46 297-302
221. Ogata J, Minami K, Segawa K, Uezono Y, Shiraishi M, Yamamoto C, Sata T, Sung-Teh K, Shigematsu A. A forskolin derivative, colforsin daropate hydrochloride, inhibits the decrease in cortical renal blood flow induced by noradrenaline or angiotensin II in anesthetized rats. Nephron Physiol 2004 96 59-64
222. Uchida M, Iida H, Iida M, Kumazawa M, Sumi K, Takenaka M, Dohi S. Both milrinone and colforsin daropate attenuate the sustained pial arteriolar constriction seen after unclamping of an abdominal aortic cross-clamp in rabbits. Anesth Analg 2005 101 9-16
223. Nakashima S, Morikawa M, Komatsu K, Matsuura A, Sato N, Abe T. Antiproliferative effects of NKH477, a forskolin derivative, on cytokine profile in rat lung allografts. J Heart Lung Transplant 2005 24 462-469
224. Onda T, Hashimoto Y, Nagai M, Kuramochi H, Saito S, Yamazaki H, Toya Y, Sakai I, Homcy C J., Nishikawa K, Ishikawa Y. Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem 2001 276 47785-47793
225. Toya Y, Schwencke C, Ishikawa Y. Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. J Mol Cell Cardiol 1998 30 97-108
226. Sawaki S, Furukawa Y, Inoue Y, Takayama S, Chiba S. Positive chronotropic and inotropic responses to novel cardiotonics, NKH477 and MCI-154 in isolated, perfused canine heart preparations. Asia Pac J Pharmacol 1993 8 133-140
227. Takeuchi M, Takaoka H, Hata K, Mori M, Yamakawa H, Yamaguchi K, Yokoyama M. NKH477: a new inotropic agent. Cardiovasc Drug Rev 1995 13 339-352
228. Ishizuka O, Hosono M, Nakamura K. Profile of cardiovascular effects of NKH477, a novel forskolin derivative, assessed in isolated, blood-perfused dog heart preparations: comparison with isoproterenol. J Cardiovasc Pharmacol 1992 20 261-267
229. Hosono M, Takahira T, Fujita A, Fujihara R, Ishizuka O, Tatee T, Nakamura K. Cardiovascular and adenylate cyclase stimulant properties of NKH477, a novel water-soluble forskolin derivative. J Cardiovasc Pharmacol 1992 19 625-634
230. Takahira T, Hosono M, Sakitama K. Cardiovascular effects of NKH477 in experimental canine heart failure. Junkan Seigyo 1995 16 196-203
231. Sanbe A, Takeo S. Effects of NKH477, a water-soluble forskolin derivative, on cardiac function in rats with chronic heart failure after myocardial infarction. J Pharmacol Exp Ther 1995 274 120-126
232. Ishizuka O, Fujita A, Kanbe E, Noguchi M, Hosono M, Sakitama K. Effectiveness of NKH477, a novel forskolin derivative, in rat cardiac preparations with desensitized beta-adrenoceptors. Nippon Yakurigaku Zasshi 1996 108 23-30
233. Mori M, Takeuchi M, Takaoka H, Hata K, Hayashi Y, Yokoyama M. Effect of NKH477, a new water-soluble forskolin derivative, on arterial-ventricular coupling and mechanical energy transduction in patients with left ventricular systolic dysfunction: comparison with dobutamine. J Cardiovasc Pharmacol 1994 24 310-316
234. Hayashida N, Chihara S, Tayama E, Kashikie H, Takaseya T, Hiratsuka R, Kai E, Enomoto N, Kawara T, Aoyagi S. Effects of colforsin daropate hydrochloride in patients undergoing coronary artery bypass surgery. Kyobu Geka 2001 54 391-395
235. Iranami H, Okamoto K, Kimoto Y, Maeda H, Kakutani T, Hatano Y. Use of colforsin daropate following cardiac surgery in a neonate. Anesthesiology 2002 97 503-504
236. Ogata J, Nakano K, Sakamoto K, Minami K. Preoperative use of colforsin daropate hydrochloride in a patient with severe cardiac function scheduled for Y-graft replacement. Anesth Analg 2001 93 1079-1080
237. Hayashida N, Teshima H, Tayama E, Chihara S, Enomoto N, Kawara T, Aoyagi S. Influence of colforsin daropate hydrochloride on internal mammary artery grafts. Circ J 2002 66 372-376
238. Hibino N, Kawai A, Uchikawa S, Chikazawa G, Kurihara T, Kihara S, Uebe K, Aomi S, Nishida H, Endo M, Koyanagi H. Cardiovascular effects of colforsin daropate hydrochloride for acute heart failure after open heart surgery. Kyobu Geka 2001 54 1016-1019